Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of pegylated interferon beta-1a in relapsing multiple sclerosis
2010-024477-39Phase 3Completed
- Sponsor
- Biogen
- Start
- Mar 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind, single-arm trial of peginterferon beta-1a in multiple sclerosis (MS), sponsored by Biogen. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 2 more. Started Mar 2011; status: completed.
02
Drugs
peginterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2010-024477-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024477-39.